Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.
Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.
Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.
Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.
Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.